
Agilent Technologies A
$ 140.3
0.46%
Quarterly report 2025-Q2
added 08-29-2025
Agilent Technologies Accounts Payables 2011-2025 | A
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 446 M | 354 M | 354 M | 340 M | 305 M | 257 M | 279 M | 475 M | 432 M | 461 M | 472 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 475 M | 257 M | 380 M |
Quarterly Accounts Payables Agilent Technologies
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 530 M | 547 M | 540 M | - | - | 479 M | 475 M | 580 M | - | 503 M | 398 M | 446 M | 416 M | 446 M | 329 M | 354 M | 354 M | 333 M | 315 M | 354 M | 354 M | 354 M | 292 M | 340 M | 340 M | 340 M | 268 M | 305 M | 305 M | 305 M | 250 M | 257 M | 257 M | 257 M | 257 M | 279 M | 279 M | 279 M | 430 M | 302 M | 302 M | 302 M | 454 M | 432 M | 432 M | 432 M | 426 M | 461 M | 461 M | 461 M | 444 M | 472 M | 472 M | 472 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 580 M | 250 M | 382 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 15.82 | 0.44 % | $ 170 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.55 | -4.63 % | $ 1.97 M | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 12.14 | 2.1 % | $ 344 M | ||
|
DexCom
DXCM
|
276 M | $ 65.83 | -1.69 % | $ 25.4 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 39.06 | 1.11 % | $ 1.08 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Exact Sciences Corporation
EXAS
|
89.6 M | $ 101.64 | 0.14 % | $ 18.8 B | ||
|
Danaher Corporation
DHR
|
1.75 B | $ 227.72 | 0.54 % | $ 166 B | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 27.0 | -0.52 % | $ 816 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
12.9 M | $ 19.98 | -2.82 % | $ 1.07 B | ||
|
Celcuity
CELC
|
9.37 M | $ 101.67 | -3.4 % | $ 4.01 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
525 K | $ 3.3 | -7.82 % | $ 105 K | ||
|
Co-Diagnostics
CODX
|
1.48 M | $ 0.29 | -14.47 % | $ 8.51 M | ||
|
IQVIA Holdings
IQV
|
322 M | $ 222.75 | 0.24 % | $ 40.4 B | ||
|
Guardant Health
GH
|
38.6 M | $ 103.7 | 1.6 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
221 M | $ 134.4 | -0.35 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
140 M | $ 197.62 | 2.4 % | $ 10.2 B | ||
|
Quotient Limited
QTNT
|
4.66 M | - | -11.32 % | $ 1.1 M | ||
|
Mettler-Toledo International
MTD
|
216 M | $ 1 410.02 | 1.15 % | $ 29.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
287 M | $ 183.96 | 0.79 % | $ 20.4 B | ||
|
NeoGenomics
NEO
|
21.6 M | $ 12.03 | 1.48 % | $ 1.52 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 6.85 | -0.22 % | $ 1.49 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 7.63 | -2.8 % | $ 989 M | ||
|
Myriad Genetics
MYGN
|
32.3 M | $ 7.04 | -2.36 % | $ 638 M | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 262.89 | -0.48 % | $ 22.1 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 184.38 | -1.18 % | $ 15.2 B | ||
|
IDEXX Laboratories
IDXX
|
114 M | $ 698.77 | -0.77 % | $ 57.6 B | ||
|
Lantheus Holdings
LNTH
|
34.6 M | $ 66.4 | -0.33 % | $ 4.59 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.48 | -2.65 % | $ 5.7 M | ||
|
Bioventus
BVS
|
23 M | $ 7.49 | -0.86 % | $ 469 M | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
15.1 M | $ 2.13 | 0.24 % | $ 540 M |